AU2012214413A1 - Method of inhibiting hamartoma tumor cells - Google Patents

Method of inhibiting hamartoma tumor cells Download PDF

Info

Publication number
AU2012214413A1
AU2012214413A1 AU2012214413A AU2012214413A AU2012214413A1 AU 2012214413 A1 AU2012214413 A1 AU 2012214413A1 AU 2012214413 A AU2012214413 A AU 2012214413A AU 2012214413 A AU2012214413 A AU 2012214413A AU 2012214413 A1 AU2012214413 A1 AU 2012214413A1
Authority
AU
Australia
Prior art keywords
hydrogen
trifluoromethyl
compound
syndrome
hamartoma tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012214413A
Other languages
English (en)
Inventor
Qi Wang
Jean J. ZHAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2012214413A1 publication Critical patent/AU2012214413A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2012214413A 2011-02-11 2012-02-09 Method of inhibiting hamartoma tumor cells Abandoned AU2012214413A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161441896P 2011-02-11 2011-02-11
US61/441,896 2011-02-11
PCT/US2012/024440 WO2012109423A1 (en) 2011-02-11 2012-02-09 Method of inhibiting hamartoma tumor cells

Publications (1)

Publication Number Publication Date
AU2012214413A1 true AU2012214413A1 (en) 2013-08-22

Family

ID=45809596

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012214413A Abandoned AU2012214413A1 (en) 2011-02-11 2012-02-09 Method of inhibiting hamartoma tumor cells

Country Status (11)

Country Link
US (1) US20140309221A1 (cg-RX-API-DMAC10.html)
EP (1) EP2673268A1 (cg-RX-API-DMAC10.html)
JP (1) JP2014505107A (cg-RX-API-DMAC10.html)
KR (1) KR20140063509A (cg-RX-API-DMAC10.html)
CN (1) CN103476765A (cg-RX-API-DMAC10.html)
AU (1) AU2012214413A1 (cg-RX-API-DMAC10.html)
BR (1) BR112013020159A2 (cg-RX-API-DMAC10.html)
CA (1) CA2826387A1 (cg-RX-API-DMAC10.html)
MX (1) MX2013009256A (cg-RX-API-DMAC10.html)
RU (1) RU2013141559A (cg-RX-API-DMAC10.html)
WO (1) WO2012109423A1 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
CN103012284A (zh) * 2012-12-26 2013-04-03 无锡捷化医药科技有限公司 一种2-氨基-5-溴嘧啶类化合物的制备方法
CA2903979A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
BR112016023811B8 (pt) 2014-04-22 2023-01-10 Piqur Therapeutics Ag Método para fabricação para derivados de triazina, pirimidina e piridina, seus intermediários e seus métodos de fabricação
CN105001151B (zh) * 2015-08-28 2017-07-14 苏州明锐医药科技有限公司 布帕尼西中间体及其制备方法
EP3458035B1 (en) * 2016-05-18 2026-08-19 Torqur AG Bimiralisib and derivatives thereof for use in the treatment of actinic keratosis
KR102483630B1 (ko) * 2016-05-18 2023-01-02 토르쿠르 아게 피부 병변의 치료
CN106905294A (zh) * 2016-07-08 2017-06-30 苏州科睿思制药有限公司 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺的晶型及其制备方法
CN106632443B (zh) * 2016-11-23 2022-06-17 山东友帮生化科技有限公司 一种2-氨基嘧啶-5-硼酸频哪酯硼酸盐的合成方法
BR112020009855A8 (pt) * 2017-11-23 2023-01-10 Piqur Therapeutics Ag Tratamento de distúrbios de pele
CN114213340B (zh) 2022-02-22 2022-06-07 北京蓝晶微生物科技有限公司 2,4-二氨基嘧啶氧化物的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
PE20120640A1 (es) * 2009-07-02 2012-06-09 Sanofi Sa Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb)

Also Published As

Publication number Publication date
KR20140063509A (ko) 2014-05-27
CN103476765A (zh) 2013-12-25
EP2673268A1 (en) 2013-12-18
CA2826387A1 (en) 2012-08-16
MX2013009256A (es) 2013-12-09
BR112013020159A2 (pt) 2016-11-08
RU2013141559A (ru) 2015-03-20
JP2014505107A (ja) 2014-02-27
WO2012109423A1 (en) 2012-08-16
US20140309221A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
US20140309221A1 (en) Method of inhibiting hamartoma tumor cells
JP7675777B2 (ja) 免疫調節剤としての複素環式化合物
CA2938280C (en) 4-amino-imidazoquinoline compounds
WO2021087018A1 (en) Pyridazinones as parp7 inhibitors
RU2675850C2 (ru) Ингибиторы alk-киназы
US10662173B2 (en) Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
US20170174679A1 (en) Heterocyclic compounds as immunomodulators
CA2888480C (en) Heteroaryl linked quinolinyl modulators of ror.gamma.t
JP5498396B2 (ja) ヒスタミンh4受容体アンタゴニストとしての4−アミノピリミジン誘導体
RU2741000C2 (ru) Производное 1,4-дизамещенного имидазола
EA019723B1 (ru) ИНГИБИТОРЫ cMET
KR20090026264A (ko) 측쇄에 스피로 고리 구조를 갖는 신규 인다졸 유도체
JP2009507896A (ja) ヒスタミンh4受容体活性の調節剤としての2−アミノピリミジン誘導体
WO2018191587A1 (en) Tam kinase inhibitors
CA3198096A1 (en) Aryl derivatives for treating trpm3 mediated disorders
KR20120083492A (ko) 신규 5-플루오로우라실 유도체
AU2013209586A1 (en) Substituted pyrimidine compounds and their use as SYK inhibitors
CN111377873B (zh) 氨基嘧啶化合物及其制备方法和用途
CA2508319A1 (en) Jnk inhibitors
EA014918B1 (ru) Замещенные бициклические пиримидоновые производные
EP3737683A1 (en) Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof
EA015123B1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛИЗОХИНОЛИНМОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ p38 КИНАЗЫ
WO2015110092A1 (zh) 4-取代吡咯并[2,3-d]嘧啶化合物及其用途
JP2016539917A (ja) Rorγtのアルキル結合キノリニルモジュレーター
EP2867215B1 (en) Tetrazole derivatives and their use as potassium channel modulators

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period